52 results about "Need treatment" patented technology

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

Treatment system (100) for treating workpieces (102), having a treatment region (108) for receiving workpieces (102) to be treated, and a plurality of operating devices (130) for performing one or more operations on the workpieces (102) to be treated.

Described herein is a novel method of treating cancer in a patient in need thereof, comprising administering a therapeutically effective amount of SARS-CoV-2 Spike 51 polypeptide.

Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.

The present invention relates to compositions comprising a combination of PI3K-ALPHA and MTOR inhibitors and methods of combination therapy for administering to subjects in need thereof for the treatment of solid tumor cancers.

Portable defibrillator (31; 41; 51; 61; 71) comprising: at least one treatment electrode (5); at least one sensor (4); at least one controller (2) connected to the at least one treatment electrode (5) and the at least one sensor (4); at least one response mechanism (6) wirelessly connected to the at least one controller (2), and wherein the at least one response mechanism (6) is activated by a patient (1) who uses the portable defibrillator (31; 41; 51; 61;71) is operable, characterized in that the at least one control (2) is configured: - in response to the detection of a patient condition requiring treatment via the at least one sensor (4), to provide a prompt issued by the portable defibrillator to the patient to elicit a response; - in response to the detection that the at least one response mechanism has not been activated, to provide treatment to the patient via the at least one treatment electrode; - in response to the detection that the patient has activated the at least one response mechanism, to prevent treatment of the patient via the at least one treatment electrode; and - to verify that it is the patient (1) who is wearing the portable defibrillator (31; 41; 51; 61;71) was, who activated the at least one response mechanism (6) by the at least one control (2) being designed to receive an input signal from the patient's body during activation of the at least one response mechanism, and to confirm, at least partially on the basis of the received input signal, that the patient (1), who is wearing the portable defibrillator (31; 41; 51; 61; 71), has activated the at least one response mechanism (6).

To provide a process for the use and preparation of fluorocyclopentenylcytosine.SOLUTION: The disclosed subject matter provides methods of using and kits comprising compounds of Formula (I): Formula (I) or hydrates, solvates or pharmaceutically acceptable salts thereof. The disclosed subject matter further provides methods for treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I), as well as processes for their preparation. The present invention also provides, among other things, an improved process for significantly reducing manufacturing costs by combining multiple steps and without isolating and purifying intermediate materials.SELECTED DRAWING: Figure 1

The invention discloses a puncture mechanical positioning device, and relates to the technical field of medical instruments. The device comprises an operating table, three bandages are arranged at the top of the operating table, and the device further comprises a moving mechanism arranged at the top of the operating table and used for transversely adjusting a puncture positioning position; the adjusting mechanism is arranged at the top of the operating table, and the adjusting mechanism is used for positioning the puncture position. The adjusting mechanism is arranged, specifically, a rotating block is rotated, the rotating block is rotated to a preset angle, a second bolt is screwed clockwise, the second bolt drives a limiting block to extrude a rotating rod downwards, the rotating rod is limited through friction force, at the moment, a puncture instrument can be inserted into the position, needing to be treated, of a patient through the rotating block, operation is easy, and operation is convenient. The puncture precision is improved to a certain extent, the influence of adjustment trouble on the treatment progress of a patient is reduced, and the treatment efficiency is improved.

The utility model relates to the technical field of moxibustion appliances, and discloses a tendon sheath moxibustion device which comprises a disc body, a fixing box capable of containing a plurality of moxibustion rods is arranged on the inner surface of the disc body, hand pads used for containing wrists or forearms are arranged on the two sides of the fixing box, the fixing box comprises a box top arranged in a hexagonal shape, and the box top is provided with a plurality of moxibustion rods. Six partition plates are connected to the periphery of the box top, and the bottoms of the six partition plates are fixed to the inner surface of the tray body. By means of the arc-shaped hand pads, a patient can place hands on the two sides of the device so as to play a role in auxiliary supporting, meanwhile, a plurality of circular openings are formed in the surface of the fixing box, moxibustion rods can be fixed in the different circular openings according to actual requirements, moxibustion can be conducted on the positions, needing to be treated, of the hands in a targeted mode, and the moxibustion effect is good. When the patient is in the sitting position, the tendon sheath moxibustion treatment requirement is met, the treatment experience and comfort of the patient are improved, and the treatment effect is ensured.

Provided herein are FLT1 binding proteins, as well as related nucleic acids, vectors, host cells, pharmaceutical compositions and kits. The present disclosure additionally provides methods of treating a subject in need thereof, including subjects in need of treatment for PAD, CLI, ANOCA, or heart failure (HF). Further provided are methods of increasing VEGF-mediated and / or PlGF-mediated signal transduction in a subject, which, in turn, increases blood flow, capillary density, capillary or coronary growth, and / or cardiac perfusion in the subject. The present disclosure further provides methods of reducing blood pressure and risk of heart failure in a subject. In exemplary embodiments, each of the methods comprise administering to the subject a pharmaceutical composition of the present disclosure. In various embodiments, the pharmaceutical composition comprises a FLT1 binding protein of the present disclosure.

The invention relates to the field of medicine, psychology and psychotherapy, as well as to computer information technology. It is based on the 8-phase psychotherapy technique of F. Shapiro for treating stress and post-traumatic stress disorder in patients. The technique involves eight consecutive phases (EMDR Association (Eye Movement Desensitization and Reprocessing), https: / / emdr.ru / news / 2018 / emdr-terapiya-obzor-razvitiya-i-mekhanizmy-deystviya). The prototype of the claimed invention is the method described in 'Intelligent virtual environment for treating anxiety exploring the Eye Movement Desensitization and Reprocessing technique' (https: / / www.researchgate.net / publication / 357606075_Intelligent_virtual_environment_for_treati ng_anxiety_exploring_the_Eye_Movement_Desensitization_and_Reprocessing_technique). A disadvantage of the prototype is that artificial intelligence is used in a limited fashion merely to determine the level of anxiety and adjust the movement of the ball in accordance therewith, and to record information. Furthermore, the prototype presupposes the involvement of a therapist, albeit to a lesser extent than in the previous version. A virtual therapist interacts with patients by means of speech, and responses to questions from a real therapist, in addition to anxiety level and heart rate, must be logged by the real therapist with the aid of a keyboard during communication with patients in virtual reality. A further disadvantage of the prototype is its focus on solving a limited number of patient problems (relieving stress and PTSD), i.e. only one protocol is used, and the fact that it cannot be used without the involvement of a therapist. The prototype is unable to provide a diagnostic assessment of problematic states of a wide range of psychological problems, select a corrective protocol, monitor the effectiveness of correction, and propose additional methods of correction. The claimed invention solves the technical problem of broadening the range of negative and problematic states that can be diagnosed (not just the level of PTSD) and making it possible to select and implement the specific protocol required to correct the problem identified, as well as to assess the effectiveness of correction and to propose additional solutions, wherein all of these aims are achieved without involving a therapist. A significant defining feature of the proposed method is the possibility of identifying a problem state in an initial step and selecting a suitable software-automated protocol tailored to each identified category of problem.

This disclosure provides a method for identifying patients requiring treatment for pressure ulcers and treating such patients with clinical interventions selected based on subcutaneous water content. This disclosure also provides a method for stratifying patient groups based on the risk of pressure ulcers and a method for reducing the incidence of pressure ulcers in care facilities. [Solution] A method is provided and includes for identifying and providing an appropriate level of pressure ulcer care to a patient based on multiple subcutaneous moisture (SEM) measurements. In one aspect, the patient receives progressively more effective intervention for pressure ulcers based on changes in SEM measurements. In another aspect, the patient receives low-intensity intervention for pressure ulcers based on changes in SEM measurements.

The disclosure provides, in various aspects, methods of treating cancer in a subject in need of treatment therefor, comprising administering to the subject a therapeutically effective amount of an osteoprotegerin inhibitor, wherein the osteoprotegerin inhibitor inhibits osteoprotegerin binding to TRAIL. In further aspects, the disclosure provides methods of achieving a therapeutic outcome in a subject in need of treatment, wherein the method comprises the administration to the subject of a treatment which inhibits OPG-mediated suppression of tumor immunity.

A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2 / COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.

Disclosed are method of treating a subject in need thereof comprising applying an alternating electric field, at a frequency for a period of time, to a target site of the subject in need thereof; and administering a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin to the subject in need thereof. Disclosed are methods of reducing viability of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin. Disclosed are methods of increasing apoptosis of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cancer cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin. Disclosed are methods of reducing the number of cancer cells comprising applying an alternating electric field, at a frequency for a period of time, to a population of cancer cells; and contacting the population of cancer cells with a combination of leucovorin calcium, fluorouracil, irinotecane hydrochloride, and oxaliplatin.

The present disclosure relates to the use of anti-BTLA antagonists, including antibodies and antigen binding fragments, in combination therapy with other immune checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1, and methods of selecting subjects in need thereof. Preferably, the lung cancer is selected from the group consisting of NSCLC and SCLC.

The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

The method for generating medical treatment recommendations comprises: scanning a relevant part among the face, head, and body of a user; mapping the scanned relevant part onto a mesh model to ensure consistent positioning; positioning the scanned relevant part in the right angle using the mesh model; detecting a set of features associated with the scanned relevant part using the mesh model; determining a treatment area that is needed to be treated based on the detected features associated with the scanned relevant part; capturing an image of the relevant part; determining at least one treatment option for the treatment area based on the captured image; simulating a treatment outcome for the determined treatment option, producing a simulated image treated with the determined treatment option; and displaying recommendation for the determined treatment option with the simulated image and relevant information.

The invention provides a sleep bruxism patient management method, an electronic device and a program product.The sleep bruxism patient management method comprises the steps that bruxism parameters and OSA parameters are obtained based on obtained data; when the molar parameter and the OSA parameter meet a first set condition, performing molar monitoring and OSA monitoring on the corresponding patient; judging whether OSA treatment is needed or not based on the molar monitoring and OSA monitoring results; when the molar parameter and the OSA parameter meet a second set condition, performing molar monitoring on the corresponding patient, judging whether the patient has bruxism or not based on a molar monitoring result, if so, managing the patient based on a bruxism scheme, and if not, performing observation management on the corresponding patient; and when the molar parameter and the OSA parameter meet a third set condition, performing observation management on the corresponding patient. And the purpose of personalized systematic management is achieved.

The present invention provides methods for treating and / or preventing breast cancer, including locally advanced or metastatic ER+ and HER2- breast cancers in patients requiring treatment, compounds for use in treatment, and combinations thereof. [Solution] Administer a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotope derivative thereof, or a prodrug thereof. JPEG2026136114000154.jpg65134

The invention provides an anti-CTLA-4 antibody or a nucleic acid encoding the anti-CTLA-4 antibody for use in treating prostate cancer in a subject, optionally in combination with a radioligand therapeutic agent such as lutetium (177LU) vipivotide tetraxetan. The invention further provides treatment methods for prostate cancer in a subject in need thereof, comprising administering the anti-CTLA-4 antibody or the nucleic acid encoding the anti- CTLA-4 antibody, optionally in combination with a radioligand therapeutic agent such as lutetium (177LU) vipivotide tetraxetan.

The present invention provides a composition for preventing or treating noise-induced hearing loss, the composition containing a CHOP protein inhibitor as an active ingredient. The present invention can achieve a fundamental treatment for permanent hearing loss, for which there is no realistic therapeutic agent, by reversibly restoring a permanent threshold shift (PTS) caused by noise. Furthermore, the present invention provides a screening method capable of rapidly searching for efficient therapeutic candidates for noise-induced hearing loss with high reliability by using the CHOP protein as a screening target. In addition, the present invention provides a composition for diagnosing noise-induced hearing loss, the composition containing an agent for measuring the expression level of the CHOP protein or a nucleic acid encoding same, and a method for diagnosing noise-induced hearing loss using the composition. The present invention predicts, with high reliability, whether a threshold shift caused by noise exposure is temporary or permanent, and thus can be useful for quickly identifying subjects in need of treatment and establishing treatment strategies early.

To provide a method for treating prostate cancer.SOLUTION: The present application relates to a method for treating and / or preventing prostate cancer, including metastatic and / or castrate-resistant prostate cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof.SELECTED DRAWING: Figure 5

A method of treating endometrial cancer in a human subject in need thereof is provided.SOLUTION: Administering to the human subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to human PD-1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) domain comprising VH complementarity determining regions (CDRs) 1, VHCDR2, and VHCDR3, wherein the sequence of each CDR is a particular sequence.SELECTED DRAWING: None

This disclosure relates to methods of managing cancer using bis-biguanide compounds, such as alexidine, and pharmaceutical compositions comprising the same. In certain embodiments, this disclosure relates to methods of treating lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating small cell lung cancer comprising administering an effective amount of a bis-biguanide compound to a subject in need thereof. In certain embodiments, the subject is diagnosed with a lung cancer. In certain embodiments, the subject is diagnosed with small cell lung cancer. In certain embodiments, the subject is a human subject.

To provide a method for treating cancer (for example, RCC) or von Hippel-Lindau disease.SOLUTION: A method for treating cancer or von Hippel-Lindau disease is provided, the method comprising administering to a human patient in need of treatment for cancer or von Hippel-Lindau disease: (a) a PD-1 antagonist; (b) a HIF-2α inhibitor; and (c) lenvatinib or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.SELECTED DRAWING: Figure 1

The present disclosure provides a method of treating breast cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a radiopharmaceutical compound having a GRPR antagonist moiety, e.g., 177 [0013] The present invention relates to a method comprising administering to the subject [0014] Lu]Lu-NeoB in combination with a CDK4 / 6 inhibitor, e.g., ribocicilib, and a therapeutically effective amount of an endocrine therapy, e.g., fulvestrant.

A method for treating cancer in a pediatric patient requiring treatment is provided, comprising administering 9-ING-41 to the patient in combination with an additional therapeutic agent.

The present invention relates to compositions comprising a combination of PI3K-ALPHA and MTOR inhibitors and methods of combination therapy for administering to subjects in need thereof for the treatment of solid tumor cancers.

Methods of treating cancer in a subject comprising administering to a subject in need of treatment an HIF-2a inhibitor, particularly Compound (I) having the structure: (I) in an amount that is about 2 times above to about five times above, or even above about 2 times above to about ten times above the amount effective to achieve maximum HIF-2a mediated peripheral EPO reduction. Methods of treating cancer in a subject, comprising administering the HIF-2a inhibitor to the subject in need of treatment.